Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label multicenter study of FRSW107 in previously treated children with severe hemophilia A
CTR20233414Phase 3Active
- Sponsor
- Kaifeng Pharmaceutical Group Co., Ltd
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human coagulation factor viii-fc fusion protein in hemophilia A, sponsored by Kaifeng Pharmaceutical Group Co., Ltd. Started Nov 2023; status: active.
02
Drugs
recombinant human coagulation factor viii-fc fusion protein
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20233414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233414.